Treatment of SMO inhibitors leads to at least a partial response in ~2/3 of advanced BCC patients, but >25% of patients discontinue therapy due to frequent, hard-to-tolerate side effects such as alopecia, dysgeusia, and muscle spasms [9]. The gene discussed is SMO; the disease is skin basal cell carcinoma.